Form 4: ESSA Pharma COO Sells Shares Under 10b5-1 Trading Plan

Peter Virsik, COO of ESSA Pharma Inc., sold 694 common shares at a weighted average price of $6.03 under a pre-arranged 10b5-1 trading plan.

Summary

• Peter Virsik, the Chief Operating Officer of ESSA Pharma Inc., sold 694 common shares of the company on October 7, 2024.
• The sale was executed under a pre-existing 10b5-1 trading plan established on August 31, 2023.
• The shares were sold at a weighted average price of $6.03 per share.
• Following the transaction, Mr. Virsik directly owns 7,776 common shares of ESSA Pharma Inc.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a positive or negative outlook on the company.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned, especially through 10b5-1 trading plans, to avoid accusations of trading on inside information. Investors often monitor insider transactions for signals about a company's prospects, but sales under 10b5-1 plans are generally viewed as less informative than discretionary trades.

Stakeholder Impact

• The sale of shares by a company officer could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates